News from nouscom A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

19 Jun, 2019, 11:30 BST Nouscom Demonstrates Preclinical Proof of Concept for Personalized Cancer Neoantigen Vaccine in Combination With Immune Checkpoint Blockade to Eradicate Large Tumors

Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today the publication of a paper...


03 Jun, 2019, 08:00 BST Nouscom - IND for NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine, Cleared by FDA to Commence Clinical Development in MSI Solid Tumors

Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that its Investigational...


05 Nov, 2018, 07:00 GMT Nouscom Strengthens Board of Directors with the Appointment of John F. McDonald as an Independent Director

Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines based on its proprietary...


29 May, 2018, 08:00 BST Nouscom Appoints Adrian Woolfson, M.D., Ph.D as Chief Medical Officer

Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines based on its clinically...


13 Nov, 2017, 08:00 GMT NousCom's Neoantigen-based Vaccine Synergizes With NKTR-214 to Cure Established Tumors in Preclinical Model

NousCom, an oncology company developing next-generation cancer vaccines based on its Exovax platform, today announced preclinical data of its...


06 Nov, 2017, 06:00 GMT NousCom Raises €42 Million Series B Financing

NousCom, an oncology company developing neoantigen based cancer vaccines based on its Exovax platform, today announced the completion of a €42...


26 Sep, 2016, 07:00 BST Nouscom Appoints New Chief Operating Officer and Strengthens the Board of Directors

Nouscom, an oncology company developing patient specific cancer vaccines based on a clinically validated genetic vaccine platform, today announced...


17 May, 2016, 08:00 BST Nouscom Concludes Successful Series A Financing of EUR 12 Million

Nouscom announced today that it has closed a EUR 12 million Series A financing co-led by LSP and Versant Ventures. The funds will be used to support...